Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR1 | P25024 | 5/20 | 0.79 |
| ▸ | CXCR2 | P25025 | 5/20 | 0.79 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.79 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.79 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.79 |
| ▸ | ALB | P02768 | 1/20 | 0.79 |
| ▸ | ESR1 | P03372 | 1/20 | 0.79 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.79 |
| ▸ | RARB | P10826 | 1/20 | 0.79 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.79 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.79 |
| ▸ | HTR2A | P28223 | 1/20 | 0.79 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.79 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.79 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.79 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.79 |
| ▸ | BLM | P54132 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4483214 | 1.00 | CXCR1 (0.79) | CXCR1CXCR2PTGS1PTGS2LMNA | |
| SCHEMBL4471196 | 1.00 | CXCR1 (0.79) | CXCR1CXCR2PTGS1PTGS2LMNA | |
| Ibuprofen SCHEMBL2889299 | 0.89 | PTGS1 (0.93) | CXCR1CXCR2PTGS1PTGS2LMNA | |
| Ibuprofen SCHEMBL19732906 | 0.89 | PTGS1 (0.93) | CXCR1CXCR2PTGS1PTGS2LMNA | |
| Ibuprofen SCHEMBL3001 | 0.88 | PTGS1 (1.00) | CXCR1CXCR2PTGS1PTGS2LMNA | |
| Ibuprofen SCHEMBL19439560 | 0.88 | PTGS1 (1.00) | CXCR1CXCR2PTGS1PTGS2LMNA | |
| Dexibuprofen SCHEMBL30091137 | 0.88 | PTGS1 (1.00) | CXCR1CXCR2PTGS1PTGS2LMNA | |
| Ibuprofen SCHEMBL19439559 | 0.88 | PTGS1 (1.00) | CXCR1CXCR2PTGS1PTGS2LMNA | |
| (R)-Ibuprophen SCHEMBL29057 | 0.88 | PTGS1 (1.00) | CXCR1CXCR2PTGS1PTGS2LMNA | |
| Ibuprofen SCHEMBL8754799 | 0.88 | PTGS1 (1.00) | CXCR1CXCR2PTGS1PTGS2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581474-B1 | CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES | DOMPE SPA (IT) | 2008-08-27 | — | — | EP | claimed |
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2024-07-18 | — | — | US | disclosed |
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| EP-3737418-B1 | POLYMERS WITH RIGID SPACING GROUPS COMPRISING BIOLOGICALLY ACTIVE COMPOUNDS | SONY GROUP CORP (JP) | 2024-02-28 | — | — | EP | disclosed |
| US-20240016799-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | MEDICON PHARMACEUTICALS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-11857545-B2 | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11815475-B2 | Method for identifying molecular structure | THE UNIVERSITY OF TOKYO (JP) | 2023-11-14 | — | — | US | disclosed |
| US-11813256-B2 | High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions | PREMIER RESEARCH INTERNATIONAL, LLC | 2023-11-14 | — | — | US | disclosed |
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | XIZANG HAISCO PHARMACEUTICALS CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-7745608-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| WO-2010048585-A2 | OLIGOMERIC COMPOUNDS AND METHODS | ISIS PHARMACEUTICALS, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| US-20100021940-A1 | Method for Determining the Activity of a Protease in a Sample | ASTRAZENECA AB (SE) | 2010-01-28 | — | — | US | disclosed |
| US-20090093510-A1 | Use of Nitrooxyderivatives of Drug for the Treatment of Muscular Dystrophies | NICOX SA (FR) | 2009-04-09 | — | — | US | disclosed |
| US-20090093510-A1 | Use of Nitrooxyderivatives of Drug for the Treatment of Muscular Dystrophies | NICOX SA (FR) | 2009-04-09 | — | — | US | disclosed |
| US-20090076174-A1 | CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | BEZWADA BIOMEDICAL, LLC (US) | 2009-03-19 | — | — | US | disclosed |
| EP-1581474-B1 | CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES | DOMPE SPA (IT) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007088123-A2 | USE OF NITROOXYDERIVATIVE OF DRUG FOR THE TREATMENT OF MUSCULAR DYSTROPHIES | NICOX S.A. (FR) | 2007-08-09 | — | — | WO | disclosed |
| EP-1581474-A1 | CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES | Dompé S.P.A. (IT) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004052830-A1 | CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES | DOMPE S.P.A. (IT) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | CXCR1 739/4885CXCR2 956/4885PTGS1 92/4885 |
| US-11813256-B2 | High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions | CPA3, PAH, HCAR2 | CXCR1 1718/4885CXCR2 1218/4885PTGS1 95/4885 |
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | AR, CYP17A1, KLK3 | CXCR1 2048/4885CXCR2 1948/4885PTGS1 1586/4885 |
| US-20090076174-A1 | CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | MME, CTSA, ALG1 | CXCR1 4812/4885CXCR2 4760/4885PTGS1 3338/4885 |
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | FAP, FIBP, FGFR1 | CXCR1 982/4885CXCR2 523/4885PTGS1 1983/4885 |
| US-20100021940-A1 | Method for Determining the Activity of a Protease in a Sample | CTRL, PRSS1, PREP | CXCR1 1352/4885CXCR2 2786/4885PTGS1 1181/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | CXCR1 3670/4885CXCR2 3060/4885PTGS1 2524/4885 |
| US-20240016799-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | VEGFA, HPGDS, ALOX5 | CXCR1 595/4885CXCR2 265/4885PTGS1 9/4885 |
| US-20090093510-A1 | Use of Nitrooxyderivatives of Drug for the Treatment of Muscular Dystrophies | TNNC1, CPT1B, SMN1; SMN2 | CXCR1 4489/4885CXCR2 3567/4885PTGS1 292/4885 |
| US-11857545-B2 | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions | HRH4, HCAR2, PAH | CXCR1 739/4885CXCR2 956/4885PTGS1 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.